Description
Masitinib (AB1010) is a novel phenylaminothiazole-type tyrosine kinase inhibitor which can inhibit PDGFR-alpha, PDGFR-beta, KIT wild type, KIT V559D, KIT delta27(murine) with IC50 of 300 nM, 50 nM, 150 nM, 3 nM and 5 nM.
Storage
2 years at -20centigrade Powder
Targets
PDGFR-alpha, PDGFR-beta, KIT(wild type), KIT(V559D), KIT(delta27)
Molecular Formula
C28H30N6OS
Chemical Name
N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide
Solubility
DMSO 100 mg/mL Water
In vitro
Masitinib (AB1010) is a novel phenylaminothiazole-type tyrosine kinase inhibitor which can inhibit PDGFR-alpha, PDGFR-beta, KIT wild type, KIT V559D, KIT delta27(murine) with IC50 of 300 nM, 50 nM, 150 nM, 3 nM and 5 nM. In vitro, masitinib can inhibit POS, HMPOS, and COS31 cell lines with IC50 of 11.04 uM, 7.09 uM, and 9.74 uM. Masitinib can also cause dose-dependent HSA cell death.
In vivo
In dogs, masitinib causes dose-time dependent OSA cell death in vitro through initiation of caspase-mediated apoptosis. Combined use of masitinib with doxorubicin in the treatment of dogs with doxorubicin-resistant malignant lymphoma.
Download Datasheet